

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Methods of Inhibiting Cancer Cells With ADNF III Antisense Oligonucleotides

I Gozes, R Zamostiano, E Gelber, A Pinhasov, M Bassan (all of Tel Aviv University), DE Brenneman (NICHD) *Serial No.:* 09/364,609 filed 30 Jul 1999. *Licensing Contact:* Susan S. Rucker; 301/496-7056 ext. 245; e-mail: sr156v@nih.gov.

This application describes methods of inhibiting the proliferation of cells using an antisense oligonucleotide derived from the polypeptide Activity Dependent Neurotrophic Factor III (ADNF III)/Activity Dependent Neuroprotective Protein (ADNP). Preferred antisense oligonucleotides are complementary to the 5' region of ADNF III/ADNP. The ability of such antisense oligonucleotides to inhibit cell proliferation has been demonstrated in *in vitro* models such as the HT29 colon cancer cell line. Based on the location of ADNF III/ADNP on chromosome 20 at 20q13, a region which has been shown via CGH to be associated with breast, ovary, colon, head and neck, brain and pancreatic cancers, ADNF III/ADNP antisense molecules might also be expected to be useful in treating one or more of these cancers.

Orally Active Peptides That Prevent Cell Damage and Death

DE Brenneman, CY Spong (both of NICHD), I Gozes, A Pinhasov, E Giladi (all of Tel Aviv University) *Serial No.:* 60/149,956 filed 18 Aug. 1999. *Licensing Contact:* Susan S. Rucker; 301/496-7056 ext. 245; e-mail: sr156v@nih.gov.

This application describes two peptides which are orally active and which have been shown in *in vitro* assays to protect against neuronal cell death. In animal model systems for Alzheimer's disease and Fetal Alcohol Syndrome the peptide have also been demonstrated to be useful. The first peptide is D-SAL, a D-isomer of the peptide SAL (SALLRSIPA) derived from Activity Dependent Neurotrophic Factor I (ADNF I). The second peptide is D-NAP, a D-isomer of the peptide NAP

(NAPVSIPQ) derived from a related protein Activity Dependent Neuroprotective Protein (ADNP)/Activity Dependent Neurotrophic Factor III (ADNF III). The peptides may be used alone or in combination. The peptides may be constructed solely of D-isomers of their amino acids or combinations of D and L amino acids. Other diseases involving neuronal cell death where D-SAL or D-NAP may be useful include Huntington's disease, epilepsy, Parkinson's disease and Tourette's syndrome.

Dated: November 9, 1999.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer.

[FR Doc. 99-30067 Filed 11-17-99; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Notice of Meeting of Recombinant DNA Advisory Committee

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Recombinant DNA Advisory Committee.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: Recombinant DNA Advisory Committee.

Date: December 8-10, 1999.

Time: December 8, 1999, 9 a.m. to 5 p.m.

Agenda: The Committee will discuss Proposed Actions under the NIH Guidelines for Research Involving Recombinant DNA Molecules (59 FR 34496) and other matters to be considered by the Committee. The Proposed Actions to be discussed will follow this notice of meeting.

Place: National Institutes of Health, 9000 Rockville Pike, Building 31, Conference Room 6, Bethesda, MD 20892.

Time: December 9, 1999, 8:30 a.m. to 5:00 p.m.

Agenda: See paragraph above for Agenda.

Place: National Institutes of Health, Building 31, Conference Room 10, Bethesda, MD 20892.

Time: December 10, 1999, 8:30 a.m. to 5:00 p.m.

Agenda: See paragraph above for Agenda.

Place: National Institutes of Health, Building 31, Conference Room 10, Bethesda, MD 20892.

Contact Person: Debra W. Knorr, Deputy Director, Office of Biotechnology Activities,

NIH, MSC 7010, 6000 Executive Boulevard, Suite 302, Bethesda, MD 20892-7010.

OMB's "Mandatory Information Requirements for Federal Assistance Program Announcements" (45 FR 39592, June 11, 1980) requires a statement concerning the official government programs contained in the Catalog of Federal Domestic Assistance. Normally NIH lists in its announcements the number and title of affected individual programs for the guidance of the public. Because the guidance in this notice covers virtually every NIH and Federal research program in which DNA recombinant molecule techniques could be used, it has been determined not to be cost effective or in the public interest to attempt to list these programs. Such a list would likely require several additional pages. In addition, NIH could not be certain that every Federal program would be included as many Federal agencies, as well as private organizations, both national and international, have elected to follow the NIH Guidelines. In lieu of the individual program listing, NIH invites readers to direct questions to the information address above about whether individual programs listed in the Catalog of Federal Domestic Assistance are affected.

Dated: November 1, 1999.

Anna Snouffer,

Acting Director, Office of Federal Advisory Committee Policy.

[FR Doc. 99-30066 Filed 11-17-99; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-4442-N-14]

Notice of Proposed Information Collection for Public Comment: Notice of Funding Availability and Application Kit for the Hispanic-Serving Institutions Work Study Program (HSI-WSP)

AGENCY: Office of Policy Development and Research, HUD.

ACTION: Notice.

SUMMARY: The proposed information collection requirement described below will be submitted to the Office of Management and Budget (OMB) for review, as required by the Paperwork Reduction Act. The soliciting public comments on the subject proposal.

DATES: *Comments Due Date:* January 18, 2000.

ADDRESSES: Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name or OMB Control Number and be sent to: Reports Liaison Officer, Office of Policy Development and Research, U.S. Department of Housing and Urban Development, 451 7th Street, SW, Room 8226, Washington, DC 20410.